Active substances
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AZARGA EYE DROPS | 5,10 mg/ml,mg/ml | Eye drops, suspension · Ocular use | 1 Dropper Container | SAR 51.35 | NCE · Prescription | NOVARTIS PHARMA AG | Valid |
NON-INFECTIOUS UVEITIS; OPEN ANGLE GLUCOMA
Decrease of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AZARGA | 02331624 | 0.5 % / W/V; 1 % / W/V | SUSPENSION · OPHTHALMIC | NOVARTIS PHARMACEUTICALS CANADA INC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Brinzolamide 10mg/ml / Timolol 5mg/ml eye drops | £3.24 | 5 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.